IP Library › Granted Patent US 12,201,595
Granted Patent B2
US 12,201,595 · App. 17/682,448 · Granted Jan 21, 2025

Compositions and methods for increasing muscle mass and strength, treating skin, reducing wear and degradation from aging and exposure and improving recovery from stress such as exercise and trauma

Inventor: Gary Calton (Sykesville, MD)
Assignee: CALWOOD NUTRITIONALS, LLC
A61K31/198A23L33/175A61K9/0053A61K31/197A61K31/405A61K31/4172A61P21/00A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,595
App. No.
17/682,448
Granted
Jan 21, 2025
Kind
B2
Abstract

Compositions including an amino acid component including: L-histidine, L-isoleucine, L-leucine, L-lysine, L-phenylalanine, L-threonine, L-tryptophan, L-valine and L-arginine and optimized levels of L-methionine. L-tryptophan content may also be elevated and optimized, and additional amino acids including arginine, L-arginine, L-citrulline, L-carnitine and L-cysteine may optionally be present. Methods of treating muscle, wounds, surgical procedures, skin conditions and other conditions using such compositions are also provided.

Claims (40)

1. A method for improving one or more of skin firmness, elasticity, and texture, comprising:

administering to a subject in need thereof a composition comprising an amino acid component, said amino acid component comprising by weight of total essential amino acids:

3-9% of L-histidine;

4-11% of L-Isoleucine;

3-37% of L-leucine;

4-12% of L-lysine;

6-17% of L-phenylalanine;

0.3-9% of L-threonine;

1-4% of L-tryptophan;

4-19% of L-valine;

27.6-60% of L-arginine;

10.3-17% of L-methionine; and

wherein the composition optionally comprises an artificial sweetener and, optionally, a flavoring component.

2. The method of claim 1 , wherein the amino acid component comprises the following concentrations of amino acids in terms of w/w %: L-histidine, 3-9%; L-isoleucine, 4-11%; L-leucine, 8.7-15.9%; L-lysine, 6.3-12%; L-methionine, 10.3-17%; L-phenylalanine, 6-17%; L-threonine, 0.3-9%; L-tryptophan, 1-4%; L-valine, 4-19%; and L-arginine, 35.2-60%.

3. The method of claim 1 , wherein the amino acid component comprises, in terms of w/w %: L-histidine, 3-9%; L-isoleucine, 4-11%; L-leucine, 8.7-15.9%; L-lysine, 6.3-11.6%; L-methionine, 10.3-17%; L-phenylalanine, 8.1-15.9; L-threonine, 0.3-9%; L-tryptophan, 1-4%; L-valine, 4-11.6%; and L-arginine, 35.2-45.5%.

4. The method of claim 1 , wherein the amino acid component comprises, in terms of w/w %: L-histidine, 5.2%; L-isoleucine, 6.6%; L-leucine, 10.3%; L-lysine, 7.6%; L-methionine, 10.3%; L-phenylalanine, 10.3%; L-threonine, 4.6%; L-tryptophan, 2.4%; L-valine, 7.6%; and L-arginine, 35.2%.

5. A method for improving one or more of skin tone, cosmetic reduction of wrinkles and fine lines, acne, scar coloration, scar reduction, scar minimization, and scar appearance, comprising:

administering to a subject in need thereof a composition comprising an amino acid component, said amino acid component comprising by weight of total essential amino acids:

3-9% of L-histidine;

4-11% of L-isoleucine;

3-37% of L-leucine;

4-12% of L-lysine;

6-17% of L-phenylalanine;

0.3-9% of L-threonine;

1-4% of L-tryptophan;

4-19% of L-valine;

27.6-60% of L-arginine;

10.3-17% of L-methionine; and

wherein the composition optionally comprises an artificial sweetener and, optionally, a flavoring component.

6. The method of claim 5 , wherein the amino acid component comprises the following concentrations of amino acids in terms of w/w %: L-histidine, 3-9%; 1-Isoleucine, 4-11%; L-leucine, 8.7-15.9%; L-lysine, 6.3-12%; L-methionine, 10.3-17%; L-phenylalanine, 6-17%; L-threonine, 0.3-9%; L-tryptophan, 1-4%; L-valine, 4-19%; and L-arginine, 35.2-60%.

7. The method of claim 5 , wherein the amino acid component comprises, in terms of w/w %: L-histidine, 3-9%; L-Isoleucine, 4-11%; L-leucine, 8.7-15.9%; 1-lysine, 6.3-11.6%; L-methionine, 10.3-17%; L-phenylalanine, 8.1-15.9; L-threonine, 0.3-9%; L-tryptophan, 1-4%; L-valine, 4-11.6%; and L-arginine, 35.2-45.5%.

8. The method of claim 5 , wherein the amino acid component comprises, in terms of w/w %: L-histidine, 5.2%; L-isoleucine, 6.6%; L-leucine, 10.3%; L-lysine, 7.6%; L-methionine, 10.3%; L-phenylalanine, 10.3%; L-threonine, 4.6%; L-tryptophan, 2.4%; L-valine, 7.6%; and L-arginine, 35.2%.

9. The method of claim 1 , wherein a dose of 1.5 g to 42 g of the said amino acid component is administered one, two, or three times a day or such doses are administered over a 24 hour period.

10. The method of claim 5 , wherein a dose of 1.5 g to 42 g of the said amino acid component is administered one, two, or three times a day or such doses are administered over a 24 hour period.

11. The method of claim 1 , wherein the administration is oral.

12. The method of claim 5 , wherein the administration is oral.

13. The method of claim 1 , wherein the composition further comprises an artificial sweetener and, optionally, a flavoring component.

14. The method of claim 13 , wherein the artificial sweetener is aspartame, acesulfame K, sucralose, rebaudioside A (rebA), advantame, neotame, or Siraitia grosvenorii fruit extracts.

15. The method of claim 5 , wherein the composition further comprises an artificial sweetener and, optionally, a flavoring component.

16. The method of claim 15 , wherein the artificial sweetener is aspartame, acesulfame K, sucralose, rebaudioside A (rebA), advantame, neotame, or Siraitia grosvenorii fruit extracts.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2022
From: CALTON, GARY
To: CALWOOD NUTRITIONALS, LLC
Reel/Frame 059263/0145 →
Continuity (3)
Continuation 16639233
Provisional Application 62547407 · Aug 18, 2017
Related Publication 20220175708A1 · Jun 9, 2022
References Cited (32)
US 4112123A · Roberts · 1978 [cited by applicant]
US 5026721A · Dudrick et al. · 1991 [cited by applicant]
US 6077828A · Abbruzzese et al. · 2000 [cited by applicant]
US 6203820B1 · Vickery · 2001 [cited by applicant]
US 6420342B1 · Hageman et al. · 2002 [cited by applicant]
US 6713501B1 · Walser · 2004 [cited by applicant]
US 8703725B2 · Troup et al. · 2014 [cited by applicant]
US 8716249B2 · Wolfe et al. · 2014 [cited by applicant]
US 9364463B2 · Ferrando et al. · 2016 [cited by applicant]
US 9597367B2 · Wolfe et al. · 2017 [cited by applicant]
US 11285124B2 · Calton · 2022 [cited by examiner]
US 20070286909A1 · Smith et al. · 2007 [cited by applicant]
US 20100267831A1 · Kobayashi et al. · 2010 [cited by applicant]
GB 2082911A · 1982 [cited by applicant]
WO 1989004165 · 1989 [cited by applicant]
WO 9109524 · 1991 [cited by applicant]
Ferrando, AA et al., “Oral Branched chain Amino Acids Decrease Whole body Proteolysis”, JPEN J Parenter Enteral Nutr., 19(1) , 1995, pp. 47 54. [cited by applicant]
Fouré, A et al., “Effects of branched-chain amino acids supplementation on both plasma amino acids concentration and muscle energetics changes resulting from muscle damage: A randomized placebo controlled trial”, Clin N… [cited by applicant]
Fouré, A et al., “Is Branched-Chain Amino Acids Supplementation an Efficient Nutritional Strategy to Alleviate Skeletal Muscle Damage? A Systematic Review”, Nutrients, 9(10), 2017, pp. [cited by applicant]
De Bandt, JP et al., “Therapeutic use of branched-chain amino acids in burn, trauma, and sepsis”, J Nutr., 136(1 Suppl):, 2006, pp. 308S-13S. [cited by applicant]
Tipton, KD , “Branched-chain Amino Acid Supplementation to Support Muscle Anabolism Following Exercise”, 2017, pp. [cited by applicant]
Tipton, KD et al., “Postexercise Net Protein Synthesis in Human Muscle from Orally Administered Amino Acids”, Am J Physiol, 276(4 Pt 1), 1999, pp. E628 34. [cited by applicant]
Paddon Jones, D et al., “Amino Acid Ingestion Improves Muscle Protein Synthesis in the Young and Elderly”, Am J Physiol Endocrinol Metab., 286(3) , 2004, pp. E321 8. [cited by applicant]
Baldissarro, E et al., “The Hip Functional Retrieval after Elective Surgery May Be Enhanced by Supplemented Essential Amino Acids”, Biomed Res Int. 2016, 2016, pp. 9318329. [cited by applicant]
Dreyer, HC et al., “Essential Amino Acid Supplementation in Patients Following Total Knee Arthroplasty”, J Clin Invest., 123(11), 2013, pp. 4654 66. [cited by applicant]
“Ncbinlmnihgov”, Estimates of Amino Acid Requirements—Recommended Dietary Allowances—NCBI Bookshelf, 2017, pp. [cited by applicant]
Borsheim et al., “Amino acid supplementation decreases plasma and liver triacylglycerols in elderly”, Nutrition, vol. 25, No. 3, 2009, pp. 281-288. [cited by applicant]
Official Communication issued in International Bureau of WIPO Patent Application No. PCT/US2018/000226, dated Dec. 17, 2018. [cited by applicant]
Extended European Search Report issued in European Patent Application No. 18 846 666.8 dated Mar. 12, 2021. [cited by applicant]
Bralley et al. Treatment of Chronic Fatigue Syndrome with specific Amino Acid Supplementation, Journal of Applied Nutrition, Vo. 46, No. 3 dated Jan. 1, 1994, pp. 74-78, XP055534423. [cited by applicant]
Glutamine producing prepn. For preventing mucosa atrophy, etc.—comprises L-leucine, L-isoleucine, L-valine, L-lysine, L-threonine, L-tryptophan, L-methionine, L-phenyl-alanine etc:, Derwent, 1994, XP002183128. [cited by applicant]
Aminoacid Compsn, for Fatigue Recovery—contains Essential Aminoacid Mixt, Contg. E.G. Valine, Leucine, Iosleucine, Lyisne and M: WPI World Patent Information Derwent, vol. 18, No. 97, 1997, XP002092563. [cited by applicant]